Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01932970 · ClinicalTrials.gov registry record · Phase 3
Study to Assess the Impact on Calcium Levels When Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) Switch From Cinacalcet to Etelcalcetide
A Phase 3 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 3
- Development phase
- 158
- Enrollment target
NCT01932970 is a Phase 3 study that has completed, run by Amgen. The registered enrollment target is 158 participants.
The verdict
NCT01932970, a Phase 3 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 158 participants
- Enrollment target
Study Summary
This is a multicenter, multiple-dose, single-arm, open-label study to assess the impact on serum corrected calcium levels when switching patients from cinacalcet to etelcalcetide (AMG 416).
Interventions
- DRUG Etelcalcetide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 158 participants |
| Start Date | 2013-08-12 |
| Est. Completion | 2017-02-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01932970
The ClinicalTrials.gov registry entry for NCT01932970 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 158 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Etelcalcetide is the first listed.
NCT01932970 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01932970 about?
NCT01932970 is a clinical study titled "Study to Assess the Impact on Calcium Levels When Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) Switch From Cinacalcet to Etelcalcetide". This is a multicenter, multiple-dose, single-arm, open-label study to assess the impact on serum corrected calcium levels when switching patients from cinacalcet to etelcalcetide (AMG 416).
What is the current status of trial NCT01932970?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 158 participants. The study started on 2013-08-12. Estimated completion is 2017-02-14.
What interventions are being tested in trial NCT01932970?
The interventions under investigation include: Etelcalcetide (DRUG).
Who is sponsoring clinical trial NCT01932970?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.